

Roberto Cauda

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3112859/roberto-cauda-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217
papers

10,059
citations

50
h-index

94
g-index

223
ext. papers

11,458
ext. citations

6.6
avg, IF

5.75
L-index

#	Paper	IF	Citations
217	The SARS-CoV-2 mu variant shouldn't be left aside: it warrants attention for its immuno-escaping ability.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	1
216	The value of electrostatic potentials of the Spike Receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 Variants. of Concern.. <i>Journal of Infection</i> , 2022 ,	18.9	3
215	The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta-plus variants: A hint to higher transmissibility?. <i>Journal of Medical Virology</i> , 2021 ,	19.7	17
214	Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant. <i>Biomolecules</i> , 2021 , 11,	5.9	2
213	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <i>Pathogens and Global Health</i> , 2021 , 115, 456-466 ^{3,1}	3.1	5
212	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 5556207	3.7	2
211	SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. <i>Journal of Medical Virology</i> , 2021 , 93, 6551-6556	19.7	32
210	People Living with HIV in the COVID-19 Era: A Case Report. <i>AIDS Research and Human Retroviruses</i> , 2021 , 37, 253-254	1.6	4
209	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1054-1065	7	45
208	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1664-1676 ^{11,6}	11.6	32
207	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14755	2.9	5
206	Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. <i>Infezioni in Medicina</i> , 2021 , 29, 54-64	3.6	1
205	Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission. <i>Journal of Medical Virology</i> , 2020 , 92, 2232-2237	19.7	21
204	A call to research: the relationship between SARS-2-CoV, ACE 2 and antihypertensives. <i>Pathogens and Global Health</i> , 2020 , 114, 165-167	3.1	2
203	Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1599-1603	5.1	4
202	Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. <i>Journal of Infection</i> , 2020 , 81, e24-e27	18.9	125
201	Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106017	14.3	57

200	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020 , 135, 106805	5.9	34
199	Liability of Health Care Professionals and Institutions During COVID-19 Pandemic in Italy: Symposium Proceedings and Position Statement. <i>Journal of Patient Safety</i> , 2020 , 16, e299-e302	1.9	9
198	Sarilumab use in severe SARS-CoV-2 pneumonia. <i>EClinicalMedicine</i> , 2020 , 27, 100553	11.3	47
197	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020 , 27, 2322-2328	6	19
196	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020 , 52, 1231-1233	3.3	20
195	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1899-1913	4.5	84
194	Ethical Criteria for the Admission and Management of Patients in the ICU Under Conditions of Limited Medical Resources: A Shared International Proposal in View of the COVID-19 Pandemic. <i>Frontiers in Public Health</i> , 2020 , 8, 284	6	10
193	Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention. <i>Antimicrobial Resistance and Infection Control</i> , 2020 , 9, 164	6.2	7
192	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020 , 82, 38-47	3.9	64
191	Off-label use of tocilizumab in patients with SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2020 , 92, 1787-1788	19.7	86
190	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. <i>HIV Research and Clinical Practice</i> , 2019 , 1-7	1.7	5
189	Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β -lactamase-producing Enterobacteriaceae infections. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 49-54	14.3	13
188	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. <i>Future Microbiology</i> , 2019 , 14, 369-372	2.9	0
187	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. <i>Clinical Infectious Diseases</i> , 2019 , 68, 355-364	11.6	163
186	Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 453-462	6.2	2
185	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019 , 47, 589-593	9.3	4
184	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2019 , 171, 695-702	8	50
183	Performance evaluation of the (1,3)- β -D-glucan detection assay in non-intensive care unit adult patients. <i>Infection and Drug Resistance</i> , 2019 , 12, 19-24	4.2	9

182	Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population. <i>Infezioni in Medicina</i> , 2019 , 27, 274-282	3.6	1
181	Systematic clinical management of patients with candidemia improves survival. <i>Journal of Infection</i> , 2018 , 77, 145-150	18.9	11
180	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 244-248	14.3	42
179	3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. <i>Antiviral Therapy</i> , 2018 , 23, 139-148	1.6	6
178	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1949-1954	5.1	14
177	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1955-1964	5.1	20
176	Verbal list learning and memory profiles in HIV-infected adults, Alzheimer® disease, and Parkinson® disease: An evaluation of the "cortical hypothesis" of NeuroAIDS. <i>Applied Neuropsychology Adult</i> , 2017 , 24, 410-419	1.9	8
175	Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing <i>Klebsiella pneumoniae</i> infections: retrospective single-center case series. <i>Infection</i> , 2017 , 45, 209-213	5.8	17
174	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized ATLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2055-2059	5.1	20
173	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017 , 29, 299-307	2.3	5
172	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1059-1067	3.7	2
171	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
170	Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. <i>Aids</i> , 2017 , 31, 457-459	3.5	32
169	Antibodies against a β -glucan-protein complex of <i>Candida albicans</i> and its potential as indicator of protective immunity in candidemic patients. <i>Scientific Reports</i> , 2017 , 7, 2722	4.9	9
168	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017 , 46, e12	7.8	13
167	Characteristics of <i>Staphylococcus aureus</i> Bacteraemia and Predictors of Early and Late Mortality. <i>PLoS ONE</i> , 2017 , 12, e0170236	3.7	38
166	Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries??. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017 , 55, 381-393	2	5
165	International infectious diseases teaching to undergraduate medical students: A successful European collaborative experience. <i>Medical Teacher</i> , 2017 , 39, 981-986	3	1

164	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1163-1171	5.1	56
163	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. <i>Journal of Infection</i> , 2016 , 73, 619-623	18.9	10
162	Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. <i>International Journal for Quality in Health Care</i> , 2016 , 28, 502-7	1.9	16
161	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. <i>Infectious Diseases</i> , 2016 , 48, 48-55	3.1	5
160	Cognitive reserve and neuropsychological functioning in older HIV-infected people. <i>Journal of NeuroVirology</i> , 2016 , 22, 575-583	3.9	25
159	Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine. <i>Journal of Immunoassay and Immunochemistry</i> , 2016 , 37, 189-200	1.8	4
158	Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. <i>PLoS ONE</i> , 2016 , 11, e0162320	3.7	13
157	A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing β Glucan and MP65 Determinants in <i>Candida</i> Species. <i>PLoS ONE</i> , 2016 , 11, e0148714	3.7	10
156	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. <i>PLoS ONE</i> , 2016 , 11, e0156523	3.7	14
155	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). <i>Clinical Neuropsychologist</i> , 2016 , 30, 1457-1468	4.4	15
154	Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3621-3622	5.1	3
153	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2133-43	5.1	334
152	Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals. <i>Journal of Infection</i> , 2015 , 70, 60-71	18.9	10
151	Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients. <i>Antiviral Therapy</i> , 2015 , 20, 433-40	1.6	9
150	Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. <i>Antiviral Therapy</i> , 2015 , 20, 441-7	1.6	27
149	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. <i>Future Microbiology</i> , 2015 , 10, 15-20	2.9	7
148	Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data. <i>Pharmacogenomics</i> , 2014 , 15, 319-27	2.6	16
147	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1185-92	5.1	85

146	Predictive models for identification of hospitalized patients harboring KPC-producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3514-20	5.9	62
145	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. <i>Journal of Infection</i> , 2014 , 68, 500-3	18.9	1
144	Liver fibrosis is associated with cognitive impairment in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19722	5.4	1
143	Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19816	5.4	7
142	Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19573-4	5.4	5
141	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19817	5.4	6
140	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 34-45		23
139	Gene Xpert MTB/RIF assay confirms its value in the first multicentre, randomised, controlled trial conducted in primary-care settings in Africa. <i>Pathogens and Global Health</i> , 2014 , 108, 127	3.1	
138	Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis. <i>Journal of Pharmacy and Pharmacology</i> , 2014 , 66, 1094-101	4.8	5
137	Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. <i>BMC Psychology</i> , 2013 , 1, 3	2.8	7
136	The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. <i>BMC Infectious Diseases</i> , 2013 , 13, 414	4	35
135	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, Atlas pilot study). <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 66, 1261-72	5.1	39
134	Variability of raltegravir plasma levels in the clinical setting. <i>Pharmacology</i> , 2013 , 92, 43-8	2.3	8
133	Mortality in patients with early- or late-onset candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 927-35	5.1	34
132	Resistance to antiretroviral drugs 2013 , 192-205		
131	Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. <i>Antiviral Therapy</i> , 2013 , 18, 153-60	1.6	45
130	Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2012 , 12, 296	4	60
129	Nosocomial acquisition of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study. <i>BMC Infectious Diseases</i> , 2012 , 12, 74	4	6

128	Effect of aging and human immunodeficiency virus infection on cognitive abilities. <i>Journal of the American Geriatrics Society</i> , 2012 , 60, 2048-55	5.6	27
127	Detecting risk and predicting patient mortality in patients with extended-spectrum β -lactamase-producing Enterobacteriaceae bloodstream infections. <i>Future Microbiology</i> , 2012 , 7, 1173-89 ^{2.9}		45
126	Multidrug-resistant <i>Proteus mirabilis</i> bloodstream infections: risk factors and outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3224-31	5.9	34
125	Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from <i>Candida albicans</i> reveal a constrained inhibitory chemotype. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 7206-13	3.4	9
124	Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. <i>Journal of Infection</i> , 2012 , 65, 439-46	18.9	14
123	Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. <i>PLoS ONE</i> , 2012 , 7, e33705	3.7	146
122	Predictors of mortality in bloodstream infections caused by <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>K. pneumoniae</i> : importance of combination therapy. <i>Clinical Infectious Diseases</i> , 2012 , 55, 943-50	11.6	705
121	High rate of Quantiferon positive and tuberculin negative tests in infants born at a large Italian university hospital in 2011: a cautionary hypothesis. <i>Pathogens and Global Health</i> , 2012 , 106, 8-11	3.1	2
120	<i>Candida</i> and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. <i>Aids</i> , 2012 , 26, 1457-72	3.5	103
119	Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e18-20	3.1	3
118	Management of serious methicillin-resistant <i>Staphylococcus aureus</i> infections: what are the limits?. <i>International Journal of Antimicrobial Agents</i> , 2011 , 37, 202-9	14.3	52
117	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. <i>Pharmacological Research</i> , 2011 , 63, 249-53	10.2	23
116	Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. <i>Vaccine</i> , 2011 , 29, 2836-9	4.1	25
115	Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. <i>Journal of Medical Virology</i> , 2011 , 83, 2057-65	19.7	10
114	Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. <i>Journal of Infection</i> , 2011 , 62, 319-21	18.9	11
113	Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. <i>Pharmacogenomics</i> , 2011 , 12, 567-76 ^{2.6}		32
112	The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1299-309	1.6	12
111	Treatment of skin and soft tissue infections due to community-associated methicillin-resistant <i>Staphylococcus aureus</i> in Europe: the role of trimethoprim-sulfamethoxazole 0010. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1471-2; author reply 1472	11.6	12

110	Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3485-90	5.9	117
109	Lipid-lowering effect of tenofovir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 682-3	5.1	22
108	Comparison of expression vectors in <i>Lactobacillus reuteri</i> strains. <i>FEMS Microbiology Letters</i> , 2010 , 308, 8-15	2.9	33
107	The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies. <i>PLoS ONE</i> , 2010 , 5, e13619	3.7	14
106	HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010 , 2, e2010034	3.2	10
105	Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2050-2	5.1	31
104	Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. <i>Clinical Infectious Diseases</i> , 2010 , 51, 456-64	11.6	20
103	Costs of bloodstream infections caused by <i>Escherichia coli</i> and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4085-91	5.9	144
102	Identification of inhibitors of drug-resistant <i>Candida albicans</i> strains from a library of bicyclic peptidomimetic compounds. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 2502-9	8.3	27
101	Prosthetic joint infection: recent developments in diagnosis and management. <i>Journal of Infection</i> , 2010 , 61, 443-8	18.9	91
100	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 109-17	5.1	64
99	Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 141-52	6.4	4
98	Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 261-7	1.6	10
97	Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4264-9	5.9	102
96	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 398-410	5.1	5
95	Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009 , 58, 299-307	18.9	124
94	Factors associated with mortality in bacteremic patients with hematologic malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 320-6	2.9	71
93	Candidaemia in patients with an inserted medical device. <i>Drugs</i> , 2009 , 69 Suppl 1, 33-8	12.1	37

92	Rapid screening tests for methicillin-resistant <i>Staphylococcus aureus</i> at hospital admission: systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2009 , 9, 546-54	25.5	89
91	Attitudes and practices of dentists treating patients infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. <i>Medical Science Monitor</i> , 2009 , 15, PH49-56	3.2	6
90	Bloodstream infections caused by extended-spectrum-beta-lactamase- producing <i>Escherichia coli</i> : risk factors for inadequate initial antimicrobial therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3244-52	5.9	86
89	Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant <i>Acinetobacter baumannii</i> calcoaceticus complex. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1130-7	5.1	40
88	Fungaemia caused by <i>Candida glabrata</i> with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1379-85	5.1	46
87	Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1. <i>Current HIV Research</i> , 2008 , 6, 306-17	1.3	11
86	Does antibiotic exposure increase the risk of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) isolation? A systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 26-38 ^{5.1}	5.1	270
85	Electronic Prescribing 2008 , 41-67		
84	Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. <i>International Journal of Antimicrobial Agents</i> , 2007 , 29, 380-8	14.3	121
83	Risk scoring and bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30 Suppl 1, S88-92	14.3	9
82	Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. <i>Journal of NeuroVirology</i> , 2007 , 13, 338-46	3.9	21
81	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1987-94	5.9	320
80	Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 1204-7	5.1	27
79	Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. <i>Journal of Infectious Diseases</i> , 2007 , 196, 1645-53	7	12
78	Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 411-7	3.1	13
77	Biofilm production by <i>Candida</i> species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 1843-50	9.7	251
76	Effects of antiretroviral therapy on tube-like network formation of human endothelial cells. <i>Biological and Pharmaceutical Bulletin</i> , 2007 , 30, 982-4	2.3	3
75	Sphingosine 1-phosphate promotes antigen processing and presentation to CD4+ T cells in <i>Mycobacterium tuberculosis</i> -infected monocytes. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 361, 687-93	3.4	9

74	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 58, 325-31	2.9	89
73	Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. <i>FEBS Letters</i> , 2007 , 581, 5897-903	3.8	32
72	On the use of chloroquine for chikungunya. <i>Lancet Infectious Diseases, The</i> , 2007 , 7, 633	25.5	16
71	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. <i>Experimental Hematology</i> , 2006 , 34, 54-65	3.1	24
70	Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. <i>Drug Development Research</i> , 2006 , 67, 806-817	5.1	10
69	Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 1238-45	5.1	146
68	Bloodstream infections caused by extended-spectrum-beta-lactamase-producing <i>Klebsiella pneumoniae</i> : risk factors, molecular epidemiology, and clinical outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 498-504	5.9	194
67	Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 3257-62	9.7	37
66	Risks and benefits of chloroquine use in anticancer strategies. <i>Lancet Oncology, The</i> , 2006 , 7, 792-3	21.7	40
65	New insights into the antiviral effects of chloroquine. <i>Lancet Infectious Diseases, The</i> , 2006 , 6, 67-9	25.5	384
64	The importance of addressing multidrug resistance and not assuming single-drug resistance in case-control studies. <i>Infection Control and Hospital Epidemiology</i> , 2006 , 27, 670-4	2	17
63	Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. <i>American Journal of Medicine</i> , 2006 , 119, 970-6	2.4	129
62	The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies. <i>Infection Control and Hospital Epidemiology</i> , 2006 , 27, 670-674	2	15
61	Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial. <i>Antiviral Therapy</i> , 2006 , 11, 321-327	1.6	9
60	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. <i>Antiviral Therapy</i> , 2006 , 11, 609-618	1.6	11
59	Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. <i>Health Policy</i> , 2005 , 74, 304-13	3.2	13
58	Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 257-66	3.1	15
57	Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2005 , 11, 219-24	3.9	19

56	Dental care and HIV-infected individuals: are they equally treated?. <i>Community Dentistry and Oral Epidemiology</i> , 2005 , 33, 447-53	2.8	10
55	Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 4175-7	9.7	97
54	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005 , 7, 161-7	1.5	3
53	HIV Protease Inhibitors Prevent Mitochondrial Hyperpolarization and Redox Imbalance and Decrease Endogenous Uncoupler Protein-2 Expression in Gp120-Activated Human T Lymphocytes. <i>Antiviral Therapy</i> , 2005 , 10, 29-45	1.6	3
52	ESBL-producing multidrug-resistant <i>Providencia stuartii</i> infections in a university hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 277-82	5.1	50
51	Hemangiomas and other congenital malformations in infants exposed to antiretroviral therapy in utero. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 305	27.4	9
50	Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 35, 223-32	3.1	92
49	Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by <i>Candida albicans</i> without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. <i>FEMS Immunology and Medical Microbiology</i> , 2004 , 41, 27-34		28
48	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2004 , 4, 46	4	55
47	HIV infection, HAART, and endothelial adhesion molecules: current perspectives. <i>Lancet Infectious Diseases</i> , 2004 , 4, 213-22	25.5	114
46	Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 35, 359-66	3.1	27
45	Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. <i>Aids</i> , 2003 , 17, 128-31	3.5	48
44	Effects of chloroquine on viral infections: an old drug against today's diseases?. <i>Lancet Infectious Diseases</i> , 2003 , 3, 722-7	25.5	854
43	Interpretation systems for genotypic drug resistance of HIV-1. <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 106, 29-34		9
42	Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. <i>Journal of Immunology</i> , 2003 , 170, 6006-15	5.3	68
41	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. <i>Aids</i> , 2003 , 17, 765-8	3.5	44
40	Multidrug-resistant <i>Pseudomonas aeruginosa</i> bloodstream infections: analysis of trends in prevalence and epidemiology. <i>Emerging Infectious Diseases</i> , 2002 , 8, 220-1	10.2	69
39	Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on <i>Candida</i> virulence and oral candidiasis in human immunodeficiency virus-infected subjects. <i>Journal of Infectious Diseases</i> , 2002 , 185, 188-95	7	68

38	Azole susceptibility patterns and genetic relationship among oral <i>Candida</i> strains isolated in the era of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002 , 31, 38-44	3.1	15
37	In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002 , 30, 369-78	3.1	18
36	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). <i>Aids</i> , 2002 , 16, 369-79	3.5	154
35	Risk factors and predictors of mortality of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteraemia in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50, 375-82	5.1	55
34	Antiapoptotic activity by HIV protease inhibitors either alone or boosted. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002 , 31, 545-6	3.1	2
33	HIV proteinase inhibitors: do they really work against <i>Candida</i> in a clinical setting?. <i>Trends in Microbiology</i> , 2002 , 10, 177-8	12.4	14
32	Differential induction of P-glycoprotein and MRP by rifamycins in T lymphocytes from HIV-1/tuberculosis co-infected patients. <i>Aids</i> , 2002 , 16, 1563-5	3.5	3
31	Recurrent venous thrombosis in a patient with haemophilia A and HIV infection. <i>Haematologica</i> , 2002 , 87, ECR04	6.6	3
30	HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001 , 27, 321-30	3.1	21
29	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001 , 27, 321-330	3.1	31
28	Potent anti-retroviral therapy with or without zidovudine for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001 , 7, 364-8	3.9	55
27	Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1628-35	11.6	42
26	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. <i>Aids</i> , 2001 , 15, 1483-91	3.5	157
25	Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency. <i>The Hematology Journal</i> , 2001 , 2, 220-7		7
24	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000 , 23, 145-151	3.1	15
23	Expression of the novel T cell activation molecule hpH4 in HIV-infected patients: correlation with disease status. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 549-57	1.6	8
22	HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000 , 23, 145-51	3.1	47
21	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. <i>Aids</i> , 2000 , 14, 2948-9	3.5	15

20	Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 21, 20-5	3.1	110
19	Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas. <i>European Journal of Immunology</i> , 1999 , 29, 2863-74	6.1	21
18	In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. <i>Journal of Infectious Diseases</i> , 1999 , 180, 448-53	7	179
17	A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. <i>Immunology Letters</i> , 1998 , 60, 19-21	4.1	10
16	Flow cytometric detection of perforin in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. <i>Immunology Letters</i> , 1998 , 60, 51-5	4.1	24
15	Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. <i>Clinical Infectious Diseases</i> , 1998 , 27, 901-2	11.6	17
14	The role of oxidative imbalance in progression to AIDS: effect of the thiol supplier N-acetylcysteine. <i>AIDS Research and Human Retroviruses</i> , 1998 , 14, 1589-96	1.6	40
13	Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 19, 490-7		25
12	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 1997 , 9, 307-10	2.2	21
11	Osteoarticular bacterial infections are rare in HIV-infected patients. 14 cases found among 4,023 HIV-infected patients. <i>Acta Orthopaedica</i> , 1997 , 68, 554-8		32
10	Age as a prognostic factor in AIDS. <i>Lancet, The</i> , 1996 , 348, 623-4	40	9
9	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 1996 , 38, 691-9	5.1	45
8	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. <i>Immunology Letters</i> , 1995 , 47, 223-6	4.1	6
7	Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. <i>Cytometry</i> , 1995 , 22, 10-5		57
6	Synthetic peptides corresponding to sequences in HIV envelope gp41 and gp120 enhance in vitro production of interleukin-1 and tumor necrosis factor but depress production of interferon-alpha, interferon-gamma and interleukin-2. <i>Viral Immunology</i> , 1991 , 4, 33-42	1.7	35
5	Role of polymorphonuclear leukocytes in infection by retroviruses with emphasis on the human immunodeficiency virus. <i>Viral Immunology</i> , 1990 , 3, 173-94	1.7	14
4	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. <i>Cellular Immunology</i> , 1988 , 115, 57-65	4.4	43
3	Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity. <i>Journal of Clinical Immunology</i> , 1987 , 7, 304-11	5.7	46

- 2 Sonographic patterns of the gallbladder in acute viral hepatitis. *Journal of Clinical Ultrasound*, **1984**, 12, 141-6 1 17
- 1 Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients 2